Reuters logo
BRIEF-Medicines Co says discontinues development of MDCO-216
November 7, 2016 / 9:57 PM / a year ago

BRIEF-Medicines Co says discontinues development of MDCO-216

Nov 7 (Reuters) - Medicines Co

* Medicines Co says discontinues development of MDCO-216, its investigational cholesterol efflux promoter

* Medicines Co - Data from Milano-pilot trial did not show drug effects on intracoronary atherosclerotic plaque sufficient to warrant further development

* Says safety profile of MDCO-216 was excellent

* Medicines Co - Discontinuation of MDCO-216 will enable co to reallocate and focus substantial additional capital onto development of its pcsk9 synthesis inhibitor

* Says does not expect to incur any charge associated with discontinuation of MDCO-216 development program Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below